Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Envision Analogue – An Introduction

    June 18, 2024 | Cancer, EMA, Envision, FDA, HTA, Market Access, analogue, oncology 

    Powered by primary payer market research, Envision is an online platform that provides forward-looking evaluations and comprehensive strategic direction for market access viability after an oncology product has received positive EMA or FDA guidance.

    tijana being interviewed

    This content was provided by Genesis Research Group

    Company Details

    Genesis Research Group logo

    Genesis Research Group

    Email
    Website

     Latest Content from  Genesis Research Group 

    Genesis Research Group’s ISPOR Europe award-winning poster authors interviewed online

    Genesis Research Group's poster 'Payer Perspective on the Impact of Real-world Evidence in Health Technology Assessments of Precision Oncology Treatments Across Europe: Results From an Online Survey' was recently named as...

    Innovating Differently: A Conversation with David W. Miller, CEO of Genesis Research Group

    A recent interview with Dr. David W. Miller, Chairman and CEO of Genesis Research Group, about his vision for the business, the changing face of research, and their unique value proposition...

    Genesis Research Group unveils enhanced US market access data analytics

    Genesis Research Group (“Genesis”), a pioneer of tech-enabled real-world evidence (RWE), health economics and outcomes research (HEOR), and market access services, announces the expansion of its real-world data analytics capabilities...

    Assessing opportunities for manufacturers to communicate the value of therapies to oncology clinical pathway (OCP) developers

    Based on insights from 15 U.S. payers and providers, this white paper explores how manufacturers can effectively engage oncology clinical pathway (OCP) developers.

    Genesis Research Group Announces Participation of CEO David W. Miller in New ITN Business Healthcare Program

    Genesis Research Group, led by newly appointed CEO, David W. Miller, is spotlighted in June’s launch of ITN Business’ “Advancing Healthcare” program for its ‘innovate differently’ approach to supporting life...

    Alice Beer of ITN Business recently interviewed David W. Miller, CEO of Genesis Research Group, on ‘Advancing Healthcare’

    ITN Business invited Genesis Research Group to contribute to a news style programme 'Advancing Healthcare' featuring key opinion leaders in the healthcare sector. Our CEO David W. Miller was one...

    How does Genesis Research Group ‘Innovate differently’?

    New Genesis Research Group CEO David W. Miller explains what we mean when we say we help our life science clients to 'Innovate differently' and transform the way they engage...

    Envision Analogue – An Introduction

    Powered by primary payer market research, Envision is an online platform that provides forward-looking evaluations and comprehensive strategic direction for market access viability after an oncology product has received positive...

    World EPA Congress 2024: ‘Shining the light on vaccine market access’ by Genesis Research Group

    A presentation with Katrin Nather, PhD, Associate Director, and Tijana Ignjatovic, Executive Director, Genesis Research Group. Contact solutions@genesisrg.com or visit www.genesisrg.com. With more and more innovative vaccines and immunization strategies...

    Fit-for-purpose matchmaking webinar: a data selection and RWE approach for both regulatory and HTA audiences

    This webinar reviews considerations for the design and data selection for RWE studies, including external control arm studies, to meet regulatory and HTA needs. Regulators and agencies responsible for market...